04. June 2018 – DÜSSELDORF, Germany

SilverSky’s portfolio company, KXTbio, has been awarded US$300,000 in US government funding by the National Institutes of Health to develop a new screening platform that will significantly reduce costs of the critical early phases of drug development. Under this grant, KXTbio will develop a high-throughput platform to screen for compounds acting on G protein-coupled receptors (GPCRs) that will reduce off-target hits, increase bona fide leads, and speed up drug discovery. After a successful completion of this project, KXTbio will be able to request up to $1.5M in additional funding to further validate and expand its innovative platform. read more